ライフサイエンスコーパス: allograft recipient

1 ediated rejection (ABMR) therapies in kidney allograft recipients.

2 grafts but not in isografts or MPO-deficient allograft recipients.

3 lidated using an independent cohort of renal allograft recipients.

4 psies, all from simultaneous pancreas-kidney allograft recipients.

5 e with abrogated T cell TGFbeta signaling as allograft recipients.

6 orine (CsA) were compared in high-risk renal allograft recipients.

7 r cause of morbidity and mortality in kidney allograft recipients.

8 d Th1- or Th2-type immune responses of heart allograft recipients.

9 n blockade-resistant rejection in T-bet(-/-) allograft recipients.

10 ituation commonly encountered in human renal allograft recipients.

11 r monitoring MFIs of de novo allo-HLA Abs in allograft recipients.

12 successfully in a large percentage of renal allograft recipients.

13 effectors in CD4 knockout (KO) skin/cardiac allograft recipients.

14 ological responses in nonhuman primate renal allograft recipients.

15 a major impact on graft outcomes in AA renal-allograft recipients.

16 generation of effector T cells in rejecting allograft recipients.

17 (BAL) of five healthy volunteers and 27 lung allograft recipients.

18 T-cell function to study 71 long-term liver allograft recipients.

19 ive rejection occurs in 10 to 20% of cardiac allograft recipients.

20 surrogate for time to graft failure in renal allograft recipients.

21 t and prevention of acute rejection in renal-allograft recipients.

22 We obtained 95 urine specimens from 87 renal allograft recipients.

23 uce tolerance in T cell depleted solid organ allograft recipients.

24 e presence of acute graft rejection in renal allograft recipients.

25 tion, some aspects are unique to solid organ allograft recipients.

26 sease (GVD) in nonhuman primate (NHP) aortic allograft recipients.

27 for time to graft failure (TTGF) in 68 renal allograft recipients.

28 id not markedly increase in ICAM-1-deficient allograft recipients.

29 correlate with active CMV infection in liver allograft recipients.

30 hypertension and graft dysfunction in renal allograft recipients.

31 a large cohort (n = 301) of pediatric kidney allograft recipients.

32 immunological responses of heart and kidney allograft recipients.

33 tubular atrophy = 59) from 168 unique kidney allograft recipients.

34 antly better renal function in primary renal allograft recipients.

35 ld be used in a preemptive strategy in liver allograft recipients.

36 characteristics of PTLD in cynomolgus kidney allograft recipients.

37 hable from the Neoral values in stable renal allograft recipients.

38 cidence of acute rejection episodes in renal allograft recipients.

39 sing knockout or monoclonal antibody-treated allograft recipients.

40 sphamide pulse therapy in sensitized cardiac allograft recipients.

41 inical rejection in tacrolimus-treated renal allograft recipients.

42 rapeutic target in the management of cardiac allograft recipients.

43 report extends the study to pediatric kidney allograft recipients.

44 o prevent AMR including in sensitized kidney allograft recipients.

45 s of donor-reactive memory Th cells as heart allograft recipients.

46 ican-American and non-African-American renal allograft recipients.

47 ologically similar to that observed in human allograft recipients.

48 es to complicate the clinical course of many allograft recipients.

49 tify operational regulatory T cells in organ allograft recipients.

50 xpression were not altered in 5-LO-deficient allograft recipients.

51 vival in a manner similar to that in ICOS-/- allograft recipients.

52 ejection in a large group of pediatric liver allograft recipients.

53 ssion, develops in approximately 1% of renal allograft recipients.

54 ct on the clinical outcome of female cardiac allograft recipients.

55 rated graft atherosclerosis (AGA) in cardiac allograft recipients.

56 , their family, or the other potential liver allograft recipients.

57 establish the risk of MN recurrence in renal allograft recipients.

58 ment of CAN in a prospective cohort of renal allograft recipients.

59 uppressive agents during treatment of kidney allograft recipients.

60 e challenges of a growing population of lung allograft recipients.

61 lated during operational tolerance in kidney allograft recipients.

62 hould be clinically explored to prepare lung allograft recipients.

63 ogeneic IgG concentrations were augmented in allograft recipients.

64 ely achieved durable chimerism in mismatched allograft recipients.

65 s a frequent, serious complication in kidney allograft recipients.

66 ostimulates a variety of immune responses in allograft recipients.

67 diseases are a major cause of death in renal allograft recipients.

68 rejection from other causes of AKI in renal allograft recipients.

69 =256) from an historical cohort of 22 kidney allograft recipients.

70 titial fibrosis (r<0.45) for size-mismatched allograft recipients.

71 Islet function was compared in autograft and allograft recipients.

72 utcome after diagnosis of cGVHD in pediatric allograft recipients.

73 ing ganciclovir when viraemia is detected in allograft recipients.

74 odel indicate that lymphocytes from tolerant allograft recipients 1) proliferate weakly to donor stra

75 ls during preemptive therapy among stem cell allograft recipients, 119 patients with CMV antigenemia

76 In the present study of 18 cardiac allograft recipients, 13 patients had negative and five

77 n allograft survival in CsA-treated LIGHT-/- allograft recipients (30 days) was considerably enhanced

78 obtained 114 urine specimens from 114 renal allograft recipients: 48 from 48 recipients with fibrosi

79 Of 831 renal allograft recipients (584 cadaveric, 247 living related)

80 s in a highly sensitized cohort of 244 renal allograft recipients (67 with preformed donor-specific a

81 In 18 allograft recipients (72%), reduced-intensity conditioni

82 ll diffusion parameters remained constant in allograft recipients after transplantation.

83 multicenter study among 106 pediatric kidney allograft recipients aged 11.4 +/- 5.9 years, we investi

84 Fifty consecutive renal allograft recipients ages 23-72 yrs who were transplante

85 Infected allograft recipients also failed to clear the virus and

86 Allograft recipients also produced pure anti-A, or pure

87 tment of hyperacute rejection in a pulmonary allograft recipient and detail the immediate clinical fi

88 is is recommended in anti-HBc-positive liver allograft recipients and anti-HBc alone individuals who

89 They occur in the majority of allograft recipients and are fatal in 17-20%.

90 the prospective database of all adult liver allograft recipients and compared to matched data from m

91 and hypertension have been reported in liver allograft recipients and contribute to an increased risk

92 mass index (BMI) is also observed in kidney allograft recipients and deceased organ donors.

93 lusion, ICV occurs in 16% of pediatric liver allograft recipients and does not appear to be related t

94 rus (HCV) infection is common in solid organ allograft recipients and is a significant cause of morbi

95 1 show enhanced homing to the draining LN of allograft recipients and promote transplant survival.

96 obliterative bronchiolitis among human lung allograft recipients and provides a novel and easily imp

97 e induction of transplant tolerance in organ allograft recipients and the development of assays that

98 tion of the immunologic relationship between allograft recipients and their grafts at any time posttr

99 p is not limited to the use of mATG in heart allograft recipients, and it is observed in nontransplan

100 and clinical characteristics of AHR in renal allograft recipients, and to further analyze the antibod

101 c Ab were 15- to 25-fold higher in CCR5(-/-) allograft recipients, and transfer of this serum provoke

102 raft recipients prompted study of DSA+ liver allograft recipients as measured by lymphocytotoxic cros

103 complement C5 deficient mice DBA/2 as islet allograft recipients as well as cobra venom factor (CVF)

104 lower in ES allograft recipients than in SS allograft recipients at 2 weeks, and ES allografts showe

105 posttransplant cardiac risk among 1102 renal allograft recipients at a single center in 1991 to 2004.

106 pare samples obtained from acutely rejecting allograft recipients at days 7, 9, and 21, we treated on

107 yte globulin (rATG) is largely used in renal allograft recipients at risk for delayed graft function

108 nt outcomes were compared between 88 cardiac allograft recipients at risk for sensitization and 26 se

109 lt diet, BP increased similarly in ES and SS allograft recipients, becoming significantly higher than

110 901 adult tacrolimus-treated primary hepatic allograft recipients between August 1995 and September 2

111 d survival times of non-human primate kidney allograft recipients both as monotherapy and most effect

112 bute to the vasculopathy observed in cardiac allograft recipients by impairing the endothelial nitric

113 Tolerance was confirmed in all limb-allograft recipients by skin grafting in vivo and by MLR

114 Renal allograft recipients can be monitored for polyomavirus-a

115 Renal allograft recipients can be successfully converted to CD

116 ineurin inhibitor nephrotoxicity in nonrenal allograft recipients can lead to end-stage renal disease

117 cular deaths was 2.56 (95% CI, 1.52-4.05) in allograft recipients compared to an age-matched populati

118 strated that the spleens of WHI-P131-treated allograft recipients contained less than 0.001% BCL-1 ce

119 usly accepted fully MHC-mismatched A/J renal allografts, recipients containing donor-reactive memory

120 of CD69 on peripheral T lymphocytes of renal allograft recipients correlates with the presence of acu

121 rement for regulatory CD4(+) T cells in skin allograft recipients could account for this differential

122 of MHC Class II and I, our protocol analyzed allograft recipients deficient in MHC Class II and b2 mi

123 -galactosidase--expressing cells into aortic allograft recipients demonstrated that intimal cells inc

124 zed prospective trial in primary adult renal allograft recipients, designed to evaluate calcineurin i

125 e adoptively transferred to subsequent naive allograft recipients despite the undiminished in vitro i

126 ns demonstrated that T-cells from irradiated allograft recipients did not exhibit a secondary alloimm

127 Neutralizing IL-4 in IFN-gamma(-/-) allograft recipients did not induce Th17, suggesting tha

128 A20 haploinsufficiency in allograft recipients did not influence TA.

129 kidney allograft recipients, long-term heart allograft recipients eventually developed humoral and ce

130 ance immunosuppression, depleted human renal allograft recipients experience rejection characterized

131 present the 23-year-old daughter of a renal allograft recipient exposed to azathioprine 75 mg/day an

132 be able to survive, expand, and suppress in allograft recipients exposed to immunosuppressants, such

133 ohort of living (79) and deceased (67) donor allograft recipients followed up over 5 years.

134 We recommend universal testing of allograft recipients for antibodies since that will help

135 assesses the net state of immune function of allograft recipients for better individualization of the

136 eans of polymerase chain reaction in 93 lung allograft recipients for functional polymorphisms in the

137 performed a cohort study of 645 adult renal allograft recipients from 1985 to 1995 to evaluate the r

138 mus were studied retrospectively in 94 liver allograft recipients from a North American and a Europea

139 Renal allograft recipients generally need to take several immu

140 leeding, and one of the left lateral segment allograft recipients had a cut-surface bile leak, which

141 28 (42%) of 67 allograft recipients had caesarean section compared with

142 Sixteen of the 17 CB allograft recipients had stable engraftment of donor cel

143 cessful management of an ABO-mismatched lung allograft recipient has not previously been described.

144 Liver allograft recipients have a greater risk of cardiovascul

145 ates of wound-healing complications in renal allograft recipients in a prospective, randomized trial

146 at mimics obliterative bronchiolitis of lung allograft recipients in human airways in vivo.

147 g-term graft survival rates were observed in allograft recipients in the 2 youngest age groups with A

148 n in the perioperative period of solid organ allograft recipients in the clinic, and correlations bet

149 d therapy was efficacious in high-risk renal allograft recipients in the first year after transplant,

150 of intragraft fibroblasts are recruited from allograft recipients in this experimental model of chron

151 We included 1518 renal allograft recipients in this prospective, observational

152 Four renal allograft recipients, including two children, with BKVAN

153 Histology in FcgammaRIII-KO cardiac allograft recipients indicated perivascular margination

154 nduced by CD154 mAb in p50- or p52-deficient allograft recipients, indicating an absolute requirement

155 /-)/CCR5(-/-) recipients and from RAG-1(-/-) allograft recipients injected with anti-K(d) antibodies

156 Eight autograft and eight allograft recipients, insulin independent or requiring m

157 ulin antibody responses were detected in all allograft recipients, irrespective of the treatment regi

158 al-gene expression in tissues from rat heart allograft recipients is highly restricted.

159 onor-specific Ab produced in CCR5(-/-) heart allograft recipients is sufficient to directly mediate g

160 Systemic hypertension affects many allograft recipients, is an important risk factor for ch

161 dence of acute rejection in heart and kidney allograft recipients, its role in lung transplantation r

162 In the allograft recipients, light signal from CD5+ passenger l

163 However, in contrast to kidney allograft recipients, long-term heart allograft recipien

164 In the heart allograft recipients, lower plasma LDH levels were obser

165 ed in first cadaveric or living donor kidney allograft recipients (n = 144) transplanted at the Unive

166 versus 45% of initially insulin-independent allograft recipients (n=154).

167 In a retrospective cohort study of renal allograft recipients (n=169), increased baseline levels

168 prospectively collected biopsies from renal allograft recipients (n=204) with stable renal function

169 Single-organ renal allograft recipients (n=2217) who had MMF introduced 6 m

170 ng-term survival (>350 days) was achieved in allograft recipients (n=6) under the 7-day protocol of c

171 sessed in spot urine of 182 outpatient renal allograft recipients on maintenance immunosuppression.

172 dii infection on survival of our 582 cardiac allograft recipients operated upon between June 1984 and

173 of rILT3 for immunosuppressive treatment of allograft recipients or patients with autoimmune disease

174 plants, highly sensitized, etc.), extrarenal allograft recipients, or alternative drug regimens such

175 The absence of CXCL9 in donor allografts, recipients, or both significantly decreased

176 ion and have extended the life expectancy of allograft recipients, posttransplant malignancy has beco

177 In renal allograft recipients presenting with graft dysfunction,

178 brief course of cyclosporine A to rat renal allograft recipients promotes progressive accumulation o

179 onor-specific antibody-positive (DSA+) renal allograft recipients prompted study of DSA+ liver allogr

180 In a large cohort of renal allograft recipients, PTLD affected 1%.

181 Renal-allograft recipients received 1.5 mg/day or 3 mg/day of

182 n therapy with BSX versus ATG in 88 AA renal allograft recipients receiving transplants at our center

183 firmed in an independent clinical setting in allograft recipients referred to our hospital with AKI.

184 mechanistic insight into immunoregulation in allograft recipients relative to obesity, an increasingl

185 creatinine, we analyzed 49,666 primary renal allograft recipients reported to the United States Renal

186 ls and 313 +/- 43 cells for CD73(-/-) and WT allograft recipients, respectively; p = 0.013).

187 62 +/- 4% and 47 +/- 5% for CD73(-/-) and WT allograft recipients, respectively; p = 0.046).

188 observed that the absence of HO-1 in aortic allograft recipients resulted in 100% mortality within 4

189 tion of anti-donor-HLA antibodies in a renal allograft recipient's serum, either at the time of or af

190 MonoIgG against normal human sera, IVIg, and allograft recipients' sera, it was observed that the num

191 189 consecutively transplanted primary renal allograft recipients, sera were collected sequentially p

192 Allograft recipients showed detectable levels of anti-HL

193 2 years in a prospective cohort of 27 liver allograft recipients showed only two patients to be cons

194 Increasing LG3 serum levels in aortic allograft recipients significantly increased neointima f

195 In allograft recipient spleens, CXCL9 and CXCL10 were expre

196 Successful allograft recipients suffer significant adverse effects

197 SRL monotherapy prevented GVD in NHP aortic allograft recipients, suggesting the value of SRL for co

198 ombination of OX38 and WT.1 had no effect on allograft recipient survival and antimurine immunoglobul

199 Forty allograft recipients T-cell depleted with Campath antibo

200 tration and albuminuria remained lower in ES allograft recipients than in SS allograft recipients at

201 In HCV-infected kidney allograft recipients, the progression of fibrosis should

202 acrolimus monotherapy has allowed many renal allograft recipients to be maintained on spaced weaning.

203 the medical records of 497 consecutive renal allograft recipients to identify patients who had receiv

204 may be used to reduce the exposure of renal allograft recipients to the nephrotoxic effects of CsA.

205 lls accumulated and divided in the spleen of allografted recipients to a greater extent than in those

206 We examined 530 renal allograft recipients transplanted at our center and foll

207 etil (MMF), and prednisone with BKN in renal allograft recipients transplanted between 1997 and 2004

208 Of 279 renal allograft recipients transplanted between March 2003 and

209 We studied 354 renal allograft recipients transplanted during 1996 to 2001 wh

210 splant antidonor HLA antibodies in 168 heart allograft recipients transplanted from October 2001 to D

211 Our objective was to determine if allograft recipients treated with a conventional immunos

212 Eighty cynomolgus monkey renal allograft recipients treated with anti-CD154 mAb were st

213 4 immunoglobulin, both in vitro and in renal allograft recipients treated with CTLA4Ig, with or witho

214 Comparable results were seen in wild-type allograft recipients treated with Sirt1 inhibitors, such

215 nt risk factors for BKV replication in renal allograft recipients treated with tacrolimus and mycophe

216 crochimerism was detected in VCA but not FTS allograft recipients up to >60 days after transplantatio

217 osuppression withdrawal in highly mismatched allograft recipients using a bioengineered stem cell pro

218 and the mean blood glucose in the 9 pancreas allograft recipients was 89 mg/dl.

219 HLA-A2-derived peptides by spleen cells from allograft recipients was also higher on days 5 and 10 as

220 The immunologic function of allograft recipients was evaluated ex vivo by enzyme-lin

221 nchymal tissue perfusion of 32 stable kidney allograft recipients was evaluated with CES before and 2

222 resence of ACAID suppressor cells in corneal allograft recipients was tested using a local adoptive t

223 enter, prospective study involving 321 renal-allograft recipients, we measured the resistive index at

224 alysis was conducted on 45 consecutive renal allograft recipients weighing < or = 15 kg, mean weight

225 Allograft recipients were administered with 4SC-101 at d

226 Two hundred forty-six first cadaveric renal allograft recipients were enrolled, and 197 were randomi

227 Renal allograft recipients were included if he or she had a bi

228 Isograft and further allograft recipients were killed, and sectioned corneas

229 More LURD allograft recipients were male (71%) compared with LRD r

230 Allograft recipients were orally administered FK778 at d

231 One hundred fifty liver allograft recipients were prospectively monitored for th

232 Nonsensitized (naive) and sensitized allograft recipients were randomized into 4 treatment gr

233 One hundred twenty renal allograft recipients were studied prospectively at 1, 3,

234 e effects of COX-2 inhibition in this model, allograft recipients were treated orally (PO) with 5 mg/

235 Forty-four de novo renal allograft recipients were treated with Campath-1H (0.3 m

236 Cynomolgus monkey heterotopic cardiac allograft recipients were treated with either IDEC-131 (

237 o-periphery CCL5 gradient in tolerant kidney allograft recipients, which controls recruitment of Treg

238 of the kidney, causing nephropathy in kidney allograft recipients, while JC virus (JCV) replication o

239 eness may be useful in identifying potential allograft recipients who are at high risk for subsequent

240 3 might be beneficial in identifying cardiac allograft recipients who are prone to develop CAV.

241 ion may provide particular benefit to kidney allograft recipients who develop delayed graft function/

242 We present cases of two renal allograft recipients who developed Strongyloides hyperin

243 f scarring on sequential biopsies from renal-allograft recipients who experienced CAN.

244 We identified 351 kidney allograft recipients who had serum levels of 25-hydroxyv

245 ectively analyzed our experience in 18 renal allograft recipients who initiated cinacalcet therapy fr

246 retrospectively PTMI among adult first renal allograft recipients who received a transplant in 1995 t

247 retrospectively reviewed 145 cadaveric renal allograft recipients who received either basiliximab (n=

248 We reviewed the records of 1166 kidney allograft recipients who received their allografts at ou

249 ectional study was performed on 227 visceral allograft recipients who survived beyond the 5-year mile

250 lyze retrospectively 420 sera from 263 renal allograft recipients who were readmitted to the hospital

251 All 1,197 renal allograft recipients who were transplanted at a single c

252 Prompted by the clinical course of a renal allograft recipient, who lost his graft because of CRS,

253 transplantation by comparing outcomes of 39 allograft recipients, who were prescribed statins for hy

254 tinctive property of CD4(+) Treg in tolerant allograft recipients, whose induction and function are i

255 se in DSA production can be induced in renal allograft recipients with 'chronic humoral rejection' by

256 Four renal allograft recipients with 'chronic humoral rejection' we

257 We obtained 24 urine specimens from 22 renal-allograft recipients with a biopsy-confirmed episode of

258 rdiovascular events and related mortality in allograft recipients with a matched population.

259 Allograft recipients with a resistive index of at least

260 is the first study to show that treatment of allograft recipients with AGI-1096 decreases the inciden

261 ifferential diagnosis and initial therapy in allograft recipients with AKI.

262 Treatment of allograft recipients with ASGM1 or with anti-NK1.1 antib

263 Included were 63 kidney allograft recipients with biopsy proven primary MN follo

264 We obtained 25 urine specimens from 8 renal allograft recipients with biopsy-confirmed BKV nephritis

265 o evidence of rejection on biopsy, and renal allograft recipients with biopsy-proven rejection were a

266 on was approximately 10-fold higher in renal allograft recipients with BKV viruria, but 58 (50.4%) of

267 served in 74 renal biopsy samples from renal allograft recipients with BKV viruria.

268 , 525 primary (90%) or secondary (10%) renal allograft recipients with cadaveric (89%) or living (11%

269 r blocker therapy is well tolerated in renal allograft recipients with chronic allograft nephropathy.

270 Patients comprised 54 renal allograft recipients with cryptococcosis in a prospectiv

271 d whether cyclosporine A (CsA)-treated renal allograft recipients with deteriorating renal function (

272 ion may provide particular benefit to kidney allograft recipients with DGF.

273 lls isolated from the spleen of unresponsive allograft recipients with donor antigen resulted in dono

274 T lymphocytes from healthy volunteers, renal allograft recipients with elevated creatinine but no evi

275 ) on clinical status and lung function in 20 allograft recipients with established BOS, confirmed by

276 We obtained 21 urine specimens from 21 renal allograft recipients with graft dysfunction and biopsy-c

277 Treatment of LIGHT+/+ allograft recipients with HVEM-Ig plus CsA also enhanced

278 Kidney allograft recipients with hypercalcemia and elevated int

279 Forty-nine adult renal allograft recipients with increased risk of rejection we

280 orneas can enhance graft survival in corneal allograft recipients with inflamed graft beds.

281 tive human interferon-gamma therapy in renal allograft recipients with invasive fungal diseases.

282 be verified in larger numbers of HIV+ renal allograft recipients with longer follow-up.

283 e outcomes of eight adult HIV+ primary renal allograft recipients with median 15 (range 8-47) months

284 present three pediatric and adolescent renal allograft recipients with multiple, recalcitrant verruca

285 risk for posttransplant malignancy in kidney allograft recipients with negative pretransplant HBc, HC

286 y-secreting cells in the blood of nine renal allograft recipients with normal kidney function before

287 cellular and humoral immunity in human renal allograft recipients with or without deteriorating renal

288 tinct microbiota structures were observed in allograft recipients with posttransplant diarrhea, AR, a

289 , open, multicenter study, CsA-treated renal allograft recipients with progressively deteriorating re

290 are effective in a small proportion of liver allograft recipients with recurrent hepatitis C.

291 Treatment of allograft recipients with SERP-1 in combination with CsA

292 iated with acute rejection, and treatment of allograft recipients with the angiogenesis inhibitor end

293 Fifteen renal allograft recipients with therapy-naive HCV genotype (GT

294 y secrete proinflammatory cytokines in renal allograft recipients with transplant glomerulopathy and

295 Granzyme B mRNA levels were lower in renal allograft recipients with UTI compared with those with A

296 zyme B mRNA in 15 urine specimens from renal allograft recipients with UTI, 29 specimens from patient

297 Administration of rabbit KC antiserum to allograft recipients within 30 min of cardiac transplant

298 d reduced acute rejection in untreated renal allograft recipients without displaying adverse effects

299 Hispanic kidney allograft recipients without evidence of preexisting dia

300 and the commonest infectious agent to affect allograft recipients, yet the virus is acknowledged rare